Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 3
Volume 3 CME Connect The Journal SPECIALTY SITES Pathology & OTHER SITES Today CME Your 2008 CME Credits: Return to Pathology & More: -- Volume 3 CME Release

interTrend Partners With The San Francisco Hep B Free Campaign to Increase Awareness and Understanding of Hepatitis B
- The 'B a Hero' Campaign Will Be Launched in August - LONG BEACH, Calif., Aug. 28 /PRNewswire/ -- interTrend Communications, a full-service Asian American marketing communications agency, joined forces with The SF Hep B Free Campaign (The SF Hep B Free)

[Original articles] Hepatic giant cells in hepatitis C virus (HCV) mono-infection and HCV/HIV co-infection
Extract not available.

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

table 3

Neurovisual Impairment: A Frequent Complication of Alpha-Interferon Treatment in Chronic Viral Hepatitis

table  3.   Effect of Interferon Treatment on Neurovisual Parameters of Eyes With Baseline Normal or Abnormal P100 Latencies of Visual Evoked Responses
Baseline P100 Latency
P Value
Normal*

(45 patients, 74 eyes)

 Abnormaldagger

(24 patients, 32 eyes)
A. Before treatment
  P100 latency (ms) 117.1 ± 5.7§§ 136.0 ± 8.1# <.0001
  P100 amplitude (µV) 7.07 ± 0.80# 6.85 ± 0.80# NS
  Electroretinogram (µV) 53.1 ± 5.2# 51.8 ± 7.2# NS
  Visual acuity§ 9.1 ± 1.6## 7.9 ± 2.4# .0035
  Visual sensitivity (db) 25.1 ± 1.0** 24.2 ± 1.5*** .0120
B. End of treatment
  P100 latency (ms) 122.3 ± 10.5§§ 136.2 ± 12.8# <.0001
  P100 amplitude (µV) 8.09 ± 8.22# 6.51 ± 1.30# NS
  Electroretinogram (µV) 53.7 ± 5.4# 52.8 ± 7.5# NS
  Visual acuity,§ 8.9 ± 1.8## 7.5 ± 2.4 .0021
  Visual sensitivity (db) 24.1 ± 1.7** 22.3 ± 3.5*** .0201
Abbreviation: NS, not significant.
* VER <127 ms.
dagger VER 127 ms.
Mean ± SD.
§ Snellen score (in 10ths).
§§ P = .0002 (paired and group comparisons).
#P = NS.
##P = .021 (paired and group comparisons).
** P < .001 (paired and group comparisons).
P = .051 (paired comparisons).
*** P = .032 (paired comparisons).

Return To Article
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 29 Aug 2008